about
Isolation and properties of an abnormal Hageman factor (Factor XII) molecule in a cross-reacting material-positive hageman trait plasmaWilliams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathwaysAnaphylactic release of a prekallikrein activator from human lung in vitro.Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikreinSeparation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.Inhibitors of kallikrein in human plasma.Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors.Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.Immunochemical studies of plasma kallikreinInteraction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge.Plasma inhibitors of the components of the fibrinolytic pathway in manInhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator.Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasmaRole of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.Amidolytic, procoagulant, and activation-suppressing proteins produced by contact activation of blood factor XII in buffer solution.The profile of vascular permeability factors in dilute guinea-pig plasma.A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor).Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complementPlasma prekallikrein: isolation, characterization, and mechanism of activation.Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin.Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen.Dissemination of contact activation in plasma by plasma kallikrein.Activation of the classical pathway of complement by Hageman factor fragment.Formation and structure of human Hageman factor fragments.Turnover of human and monkey plasma kininogens in rhesus monkeys.Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XIIPotentiation of the function of Hageman factor fragments by high molecular weight kininogen.Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.Purification of high molecular weight kininogen and the role of this agent in blood coagulation.Plasma kallikrein activation and inhibition during typhoid fever.Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate.Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.Activation of arginine and tyrosine esterase in serum from patients with hereditary angio-oedema.Structural changes accompanying enzymatic activation of human Hageman factor.Bradykinin and the pathogenesis of hereditary angioedema.The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
P2860
Q24302040-17E29F18-CF15-4DB1-A478-0490446FC78EQ24634211-4C5BDC91-9450-4AC6-96E5-78BCA5C09DDCQ28365898-649BE6B5-74F3-46C3-BF0B-B4F27053C9D6Q33982766-87973A29-98D5-4727-A640-F7D0A07E4F7DQ34064933-C9D479EC-0466-4F97-B8A1-C9349D5BE036Q34071315-4A8D7F5C-1F84-4796-93B0-CB3C00936654Q34462259-E259409A-855D-4455-8197-2785269A2B5DQ34462395-C254EB47-5C61-4FAE-A5F2-934C38647912Q34471111-086726D3-7DAD-401A-952D-94BF9DEBFE6CQ34478124-1544EBD9-54C2-406F-989A-D77CC19E439AQ34505524-F22287C6-0EA7-48D8-937C-3B2434C29996Q34505602-4ED4A242-B0E3-467B-8158-6DA5E7C0ED99Q34511821-492F7F3A-04F3-485A-B662-253309556262Q35037706-647F8988-3612-4D9C-A494-628B8FF8260CQ35058622-669D06C4-35FD-485C-A2EC-EC76F893FE57Q35207230-A7C5A7AF-6849-4FD7-A155-4E989BEA4FDCQ35208694-C71A0360-9EA1-4EE3-A3D9-F09FCEB68BDCQ35561035-EB09B5FC-788A-45E2-A56C-1482D5AE4FB5Q36130081-F2EEFCF9-D9D7-40CA-87A7-7DC6D17A7376Q36270878-0236818E-70C4-4AE3-B985-2398CCF1FB65Q36270989-46D10356-A176-4EE0-AEBE-4F61C140266AQ36271325-5A25F480-0FA0-497A-8282-49FA84C7BEC1Q36271407-1A6B2B07-1B18-499E-ADAC-08F686D6CF7CQ36273769-38E7F5AD-8B8B-4773-B2CD-45E30531E76EQ36340730-8F95FFEE-D27E-43AE-B90C-71D8E251FFCAQ36343908-6E1255E9-9090-4CB8-984D-18740FD7E3E0Q36344568-0AB96379-3A7E-4C00-A332-04D85E74944BQ36986168-79FE05C2-5927-43D7-A0DF-BA78AF660FB3Q37034738-69CF9244-C35C-410C-9B9E-4800311E273BQ37042626-A79EBA81-1C67-44B8-8490-F0C8822B9009Q37045271-B38CC653-7162-45FB-B5A1-B6DF39EAA3C7Q37045297-9072BA3E-9550-491C-B835-95D18E349766Q37046547-BD86E4D7-F8AB-4B41-8439-5326B1216E24Q37050492-35D19E1D-2B65-4BEA-AFEE-40A891F20553Q37312644-2BE54E8B-4C52-4651-AEB8-8FE74C9030A8Q38677670-44783BD9-8EC1-4D3C-8AC8-2A52D19276BCQ39993826-307248A2-E95C-4404-929F-8A8269BDA8FCQ40368436-D8F13025-9E15-41FA-A9C1-0ABB7CD2C54AQ40621981-C8090803-1329-4218-8A6C-183E19870B3FQ40690900-1CE3E0EE-9FB4-4948-A640-8C1F0F1E8670
P2860
description
1970 nî lūn-bûn
@nan
1970年の論文
@ja
1970年学术文章
@wuu
1970年学术文章
@zh
1970年学术文章
@zh-cn
1970年学术文章
@zh-hans
1970年学术文章
@zh-my
1970年学术文章
@zh-sg
1970年學術文章
@yue
1970年學術文章
@zh-hant
name
A pre-albumin activator of prekallikrein.
@en
A pre-albumin activator of prekallikrein.
@nl
type
label
A pre-albumin activator of prekallikrein.
@en
A pre-albumin activator of prekallikrein.
@nl
prefLabel
A pre-albumin activator of prekallikrein.
@en
A pre-albumin activator of prekallikrein.
@nl
P1476
A pre-albumin activator of prekallikrein.
@en
P2093
P304
P407
P577
1970-10-01T00:00:00Z